deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04955743

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

A Multicenter Phase 2 Trial to Evaluate Intracranial Response to Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma Who Are Anti-PD1/PD-L1 Experienced

Sponsor: Merck Sharp & Dohme LLC

Conditions Brain Metastases Lenvatinib Melanoma Metastatic Melanoma PD1/PD-L1 Experienced Pembrolizumab Renal Cell Carcinoma
Interventions Lenvatinib Pembrolizumab
Updated 15 times since 2021 Last updated: Nov 18, 2025 Started: Feb 9, 2022 Primary completion: May 28, 2025 Completion: May 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of activity in the drugs

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Brain Metastases trials with similar outcome

Browse all Brain Metastases trials

A PHASE2 clinical study on Brain Metastases and Lenvatinib, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Dec 2023 · 7 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – ~Dec 2025 · 5 months · monthly snapshot~Dec 2025 – present · 8 months · monthly snapshot

Change History

15 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE2

  2. Jul 2025 — Dec 2025 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. May 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE2

  5. Jan 2025 — Apr 2025 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  4. Dec 2023 — Mar 2024 [monthly]

    Recruiting PHASE2

  5. May 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  6. Sep 2022 — May 2023 [monthly]

    Recruiting PHASE2

  7. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  8. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Dec 2021 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

  10. Sep 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Yale University
Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations